UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 10-K/A

(Amendment No. 1)



[X] ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



For the Fiscal Year Ended: December 31, 2015



or



[  ] TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



AKERS BIOSCIENCES, INC.

(Exact name of registrant as specified in its
charter)



|New
    Jersey                      |  |              |  | 22-2983783            
|----------------------------------- |  | ------------ |  | ----------------------
|(State or other jurisdiction
    of |  | (Commission  |  | (I.R.S. Employer      
|incorporation or
    organization)  |  | File Number) |  | Identification Number)



201 Grove Road

Thorofare, New Jersey USA 08086

(Address of principal executive offices, including
zip code)



(856) 848-8698

(Registrant’s telephone number, including
area code)



Securities registered pursuant to Section 12(b)
of the Act: None



Securities registered pursuant to Section 12(g)
of the Act: Common Stock, no par value



Indicate by check mark if the registrant is
a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes [  ] No [X]



Indicate by check mark if the registrant is
not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [  ] No [X]



Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing
requirements for the last 90 days. Yes [X] No [  ]



Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files). Yes [X] No [  ]



Indicate by check mark if disclosure of delinquent
filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained,
to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III
of this Form 10-K or any amendment to this Form 10-K. Yes [  ] No [  ]



Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of
“large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act.



|Large Accelerated Filer [  ] |  | Accelerated Filer [  ]       
|---------------------------- |  | -----------------------------
|                             |  |                              
|Non-Accelerated Filer [  ]   |  | Smaller reporting company [X]



Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]



The aggregate market value of the voting and
non-voting common equity held by non-affiliates of the registrant on June 30, 2015, based on a closing price of $4.35 was $22,380,041.
As of March 25, 2016, the registrant had 5,425,045 shares of its common stock, no par value per share, outstanding.



Documents Incorporated By Reference: None.




















EXPLANATORY NOTE



This Amendment (the “Amendment”)
to Akers Biosciences, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities
and Exchange Commission on March 30, 2016 (the “Form 10-K”), is being filed with the limited purpose of adding a signature
to the Report of Independent Registered Public Accounting Firm (the “Audit Report”) that was previously filed with
the Form 10-K on page F-2. The corrected Audit Report is below. All other items in the Form 10-K are unchanged.













SIGNATURES



Pursuant to the requirements of Section 13
or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.



|                     | AKERS BIOSCIENCES, INC.
|-------------------- | -----------------------
|                     |                        
|Date: March 30, 2016 | By:                    
|                     | Name:                  
|                     | Title:                 
|                     |                        
|Date: March 30, 2016 | By:                    
|                     | Name:                  
|                     | Title:                 



Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.



|Name                      |  | Position           |  | Date          
|------------------------- |  | ------------------ |  | --------------
|                          |  |                    |  |               
|/s/
    Raymond Akers Jr. |  | Executive Chairman |  | March 30, 2016
|Raymond Akers Jr.         |  |                    |  |               
|                          |  |                    |  |               
|/s/
    Thomas Knox       |  | Director           |  | March 30, 2016
|Thomas Knox               |  |                    |  |               
|                          |  |                    |  |               
|/s/
    Brandon Knox      |  | Director           |  | March 30, 2016
|Brandon Knox              |  |                    |  |               
|                          |  |                    |  |               
|/s/
    Robert E Andrews  |  | Director           |  | March 30, 2016
|Robert E. Andrews         |  |                    |  |               
|                          |  |                    |  |               
|/s/
    Dr. Raza Bokhari  |  | Director           |  | March 30, 2016
|Dr. Raza Bokhari          |  |                    |  |               











REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM



To the Board of Directors and Stockholders
of

Akers Biosciences, Inc. and Subsidiaries



We have audited the accompanying consolidated
balance sheets of Akers Biosciences, Inc. and Subsidiaries (the “Company”) as of December 31, 2015 and 2014, and the
related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for
the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility
is to express an opinion on these consolidated financial statements based on our audits.



We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such an opinion. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.



In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the consolidated financial position of Akers Biosciences,
Inc. and Subsidiaries at December 31, 2015 and 2014, and the consolidated results of their operations and their cash flows for
the years then ended, in conformity with accounting principles generally accepted in the United States of America.



/s/ Morison Cogen LLP

Blue Bell, Pennsylvania

March 30, 2016